Crucial tools for Covid-19 Omicron research
AMSBIO has introduced further essential tools for SARS-CoV-2 researchers to help decipher the COVID-19 B.1.1.529 variant.
New to the AMSBIO range are recombinant proteins, easy-to-perform assay kits, Omicron pseudotyped lentiviruses and spike neutralizing antibodies for use in functional assays to block SARS-CoV-2 spike protein and ACE2 binding.
Screening for small molecule and antibody inhibitors is an important factor in assisting the discovery of treatments and vaccines for COVID-19 variants. ACE2, Spike, and the 3CL/Main protease are all potential therapeutic targets for the SARS-CoV-2 viral infection triggering this highly infectious disease. AMSBIO has introduced a range of Omicron assay kits for testing interactions with these targets and their respective pathways. Requiring no time-consuming wash steps, these easy-to-perform assay kits come in a variety of read-out detection methods including TR-FRET, fluorogenic, colorimetric, and chemiluminescence. These new kits are ideal for use in validation studies and suitable for rapid high-throughput screening of SARS-CoV-2 inhibitors.
Expressing B1.1.529 S protein, Omicron pseudoviruses from AMSBIO are invaluable tools for measuring inhibitory molecules when used in tandem with ACE2 recombinant cell lines or for measuring the activity neutralizing antibodies. AMSBIO’s novel Omicron lentiviruses contain either luciferase or eGFP reporter genes that provide convenient readout of transduction.
Also new to the market are a range of Omicron variant recombinant proteins including Nucleocapsid protein, 3CL Protease and Spike trimer (S1+S2) developed for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.
For further information on the latest tools for COVID-19 Omicron research please visit https://www.amsbio.com/sars-cov-2-spike-mutants or contact AMSBIO on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / [email protected].
About AMSBIO
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics, and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion, and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins, and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognised as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications. This includes GMP cryopreservation technology, and high-quality solutions for viral delivery (lentivirus, adenovirus, and adeno-associated virus.